Jazgul Abjamilova's Article - Thyroid Hormonal Responses to Biological Treatments Understanding Their Role in Rheumatoid Arthritis

 

 

Thyroid Hormonal Responses to Biological Treatments

Understanding Their Role in Rheumatoid Arthritis

 

Article By

Kartikay Dhillon

Avtar Singh

Deepak

Abhinav Kumar Sharma

Email : abhinavosh13@gmail.com

 

Under the Guidance of

Jazgul Abjamilova

Deptt of Pediatrics

ORCID - https://orcid.org/0000-0001-8028-3343

 

Abstract

Living with rheumatoid arthritis (RA) means navigating a world of joint pain, fatigue, and the constant push to find treatments that restore balance to an overactive immune system. Biological therapies, like TNF inhibitors and IL-6 blockers, have been game-changers, calming inflammation and offering hope for better days. But their impact reaches beyond the joints, touching the thyroid—a small gland with a big role in energy, mood, and metabolism. This article dives into the intricate dance between these powerful drugs and thyroid hormones, exploring how they can both help and challenge the body’s delicate equilibrium. For people with RA, who are already more likely to face thyroid issues like hypothyroidism or Hashimoto’s, understanding this connection is deeply personal. We unravel the science—how biologics tweak hormone levels, sometimes easing fatigue or, in rare cases, sparking new thyroid concerns. Through real-world insights, patient stories, and practical advice, we aim to empower those with RA to advocate for their health, ensuring their treatment journey supports both their joints and their thyroid, for a fuller, more vibrant life.

Introduction: The Intersection of Thyroid and Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune condition that causes painful inflammation in the joints, fatigue, and sometimes damage to other organs. For those living with RA, managing symptoms and halting disease progression often involves advanced treatments, including biological therapies. These treatments, designed to target specific immune system components, have revolutionized RA care. However, their effects extend beyond the joints, influencing other systems in the body, including the thyroid gland—a small but mighty organ that regulates metabolism, energy, and overall health through hormones like thyroxine (T4) and triiodothyronine (T3).

The thyroid and RA share a fascinating and complex relationship. Autoimmune diseases often cluster together, meaning someone with RA may also have a higher risk of thyroid conditions like hypothyroidism (underactive thyroid) or Hashimoto’s thyroiditis. Biological treatments for RA, such as tumor necrosis factor (TNF) inhibitors or interleukin-6 (IL-6) blockers, can influence thyroid hormone levels, sometimes in unexpected ways. Understanding these interactions is crucial for patients and healthcare providers to optimize treatment plans and improve quality of life.

In this article, we’ll dive deep into how biological treatments for RA affect thyroid hormones, explore the mechanisms behind these responses, and discuss their implications for patients. Whether you’re living with RA, supporting someone who is, or simply curious about the science, this guide will walk you through the details in a clear and relatable way.

- 1: The Basics of Rheumatoid Arthritis and Biological Treatments

Rheumatoid arthritis is more than just joint pain—it’s a systemic condition where the immune system mistakenly attacks the body’s own tissues, primarily the synovium (the lining of the joints). This leads to swelling, stiffness, and, over time, joint damage. RA affects about 1% of the global population, with women being two to three times more likely to develop it than men.

Traditional treatments for RA include nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce pain, corticosteroids to control inflammation, and disease-modifying antirheumatic drugs (DMARDs) like methotrexate to slow disease progression. However, for many patients, these treatments aren’t enough, or they come with significant side effects. This is where biological therapies come in.

Biological treatments, or biologics, are a class of drugs made from living organisms. They target specific molecules in the immune system that drive inflammation in RA. Some common biologics include:

- TNF inhibitors (e.g., adalimumab, etanercept): These block tumor necrosis factor, a cytokine that promotes inflammation.

- IL-6 inhibitors (e.g., tocilizumab): These target interleukin-6, another inflammatory cytokine.

- B-cell inhibitors (e.g., rituximab): These deplete B cells, which produce harmful antibodies in RA.

- T-cell co-stimulation blockers (e.g., abatacept): These interfere with T-cell activation, a key step in the autoimmune process.

Biologics have transformed RA management, helping many patients achieve remission or low disease activity. But their effects aren’t limited to the immune system. Because RA is a systemic disease, and biologics act on pathways that influence multiple organs, these drugs can impact other systems, including the thyroid.

- 2: The Thyroid’s Role in Health and Its Connection to RA

The thyroid gland, located in the neck, produces hormones that regulate nearly every bodily function, from heart rate to body temperature to energy levels. The main thyroid hormones are T4 and T3, which are controlled by thyroid-stimulating hormone (TSH) from the pituitary gland. When thyroid function is disrupted, it can lead to hypothyroidism (low hormone levels, causing fatigue, weight gain, and depression) or hyperthyroidism (high hormone levels, causing anxiety, weight loss, and rapid heartbeat).

Autoimmune diseases like RA and thyroid disorders often go hand in hand. For example, Hashimoto’s thyroiditis, an autoimmune condition where the immune system attacks the thyroid, is more common in people with RA. Studies suggest that up to 30% of RA patients may have some form of thyroid dysfunction, compared to about 10% of the general population. This overlap likely stems from shared genetic and environmental factors that predispose individuals to autoimmunity.

In RA, chronic inflammation can also affect thyroid function indirectly. Cytokines like TNF and IL-6, which are overactive in RA, can alter thyroid hormone metabolism, leading to a condition called non-thyroidal illness syndrome (NTIS). In NTIS, T3 levels drop, and reverse T3 (an inactive form of T3) rises, even though TSH levels may appear normal. This can cause symptoms like fatigue and brain fog, which overlap with RA symptoms, making it tricky to pinpoint the cause.

- 3: How Biological Treatments Influence Thyroid Hormones

Biological treatments for RA target the same inflammatory pathways that can disrupt thyroid function, so it’s no surprise that they can influence thyroid hormone levels. However, the effects vary depending on the drug, the patient’s baseline thyroid status, and the duration of treatment. Let’s break down the key mechanisms:

1. TNF Inhibitors

   TNF is a major player in RA inflammation, but it also affects thyroid hormone metabolism. High TNF levels can suppress TSH secretion and reduce T3 production. By blocking TNF, drugs like adalimumab and etanercept can restore normal thyroid hormone levels in some patients. For example, studies have shown that after starting TNF inhibitors, patients with RA and NTIS may see an increase in T3 and a decrease in reverse T3, improving energy levels.

   However, TNF inhibitors can also trigger autoimmune thyroiditis in rare cases. This paradox—where a drug that calms one autoimmune condition sparks another—highlights the complexity of the immune system.

2. IL-6 Inhibitors

   IL-6 is another cytokine that drives inflammation and affects thyroid function. It can inhibit the conversion of T4 to T3 and increase reverse T3 levels. Tocilizumab, an IL-6 inhibitor, has been shown to normalize T3 levels in some RA patients by reducing inflammation. This can lead to better energy and mental clarity, which patients often notice as a “bonus” effect of treatment.

   On the flip side, IL-6 inhibitors may unmask underlying thyroid issues. For example, if a patient has subclinical hypothyroidism (mildly elevated TSH with normal T4), the immune-modulating effects of tocilizumab could tip the balance toward overt hypothyroidism.

3. B-Cell and T-Cell Targeted Therapies

   Rituximab and abatacept, which target B cells and T cells, respectively, have less direct effects on thyroid hormones. However, by reducing overall immune activity, they can stabilize thyroid function in patients with coexisting autoimmune thyroid disease. Rarely, rituximab has been linked to thyroid dysfunction, possibly due to its profound effects on antibody-producing B cells.

4. General Immune Modulation

   All biologics alter the immune system’s balance, which can affect the hypothalamic-pituitary-thyroid (HPT) axis—the system that regulates TSH and thyroid hormone production. Chronic inflammation in RA can suppress the HPT axis, leading to lower thyroid hormone levels. By reducing inflammation, biologics may “reactivate” the HPT axis, improving thyroid function. However, this reactivation can sometimes overshoot, causing transient hyperthyroidism.

- 4: Clinical Evidence and Real-World Implications

Research on thyroid responses to biologics in RA is still evolving, but several studies provide valuable insights. A 2018 study published in Clinical Rheumatology found that RA patients treated with TNF inhibitors had significant improvements in T3 levels after six months, particularly those with baseline NTIS. Another study in Thyroid (2020) reported that tocilizumab increased free T4 levels in RA patients with subclinical hypothyroidism, suggesting a beneficial effect on thyroid function.

However, not all findings are positive. A small subset of patients on biologics develops new thyroid dysfunction, such as Hashimoto’s thyroiditis or Graves’ disease. A 2019 case series in Autoimmunity Reviews described three RA patients who developed hypothyroidism after starting TNF inhibitors, possibly due to immune reconstitution—a phenomenon where the immune system “resets” and attacks new targets.

For patients, these findings have real-world implications. Imagine living with RA, battling joint pain and fatigue, only to discover that your treatment might be affecting your thyroid, causing additional symptoms like weight gain or anxiety. This underscores the need for regular monitoring. Endocrinologists and rheumatologists often recommend checking TSH, free T4, and free T3 levels before starting biologics and periodically during treatment, especially if symptoms like fatigue or mood changes persist.

- 5: Practical Considerations for Patients and Providers

If you have RA and are considering or already using biologics, here’s what you need to know about thyroid health:

1. Baseline Thyroid Testing

   Before starting a biologic, ask your doctor to check your thyroid function with a full panel (TSH, free T4, free T3, and thyroid antibodies like anti-TPO and anti-thyroglobulin). This establishes a baseline and helps identify any preexisting thyroid issues.

2. Symptom Awareness

   Thyroid dysfunction can mimic RA symptoms, so pay attention to changes like unexplained weight gain/loss, extreme fatigue, hair loss, or heart palpitations. Keep a symptom diary and share it with your healthcare team.

3. Regular Monitoring

   Thyroid function can change over time, especially in the first year of biologic therapy. Ask your doctor how often you should have thyroid tests—typically every 6–12 months, or sooner if symptoms arise.

4. Teamwork Between Specialists

   If you have both RA and a thyroid condition, your rheumatologist and endocrinologist should communicate. Biologics can affect both conditions, and treatments like levothyroxine (for hypothyroidism) or methimazole (for hyperthyroidism) may need adjustment.

5. Lifestyle Support

   Supporting your thyroid health through diet and lifestyle can complement medical treatment. Ensure adequate intake of iodine (found in seafood and dairy), selenium (in Brazil nuts and eggs), and zinc (in meats and legumes), as these nutrients support thyroid function. Manage stress with mindfulness or gentle exercise, as stress can exacerbate both RA and thyroid issues.

For healthcare providers, a multidisciplinary approach is key. Rheumatologists should screen for thyroid dysfunction in RA patients, especially those with persistent fatigue or poor response to biologics. Collaboration with endocrinologists can ensure that thyroid issues are caught early and managed effectively.

- 6: Looking Ahead: Research and Hope for the Future

The interplay between biological treatments, thyroid hormones, and RA is a rapidly evolving field. Ongoing research is exploring several exciting areas:

- Personalized Medicine: Genetic and biomarker studies may help predict which RA patients are at risk for thyroid dysfunction on biologics, allowing for tailored treatment plans.

- New Biologics: Next-generation biologics, such as Janus kinase (JAK) inhibitors, are being studied for their effects on thyroid function. Early data suggest they may have a different impact than traditional biologics.

- Mechanistic Insights: Scientists are delving deeper into how cytokines like TNF and IL-6 interact with the HPT axis, which could lead to new therapies that target both RA and thyroid dysfunction simultaneously.

For patients, the future holds promise. Advances in understanding thyroid responses to biologics could lead to better symptom management, fewer side effects, and improved quality of life. In the meantime, staying informed and proactive about your health is the best way to navigate the complexities of RA and thyroid care.

Conclusion: A Holistic Approach to RA and Thyroid Health

Living with rheumatoid arthritis is challenging, but biological treatments have given many patients a new lease on life. However, their effects on the thyroid remind us that the body is an interconnected system—what helps one part may influence another. By understanding how biologics affect thyroid hormones, patients and providers can work together to catch issues early, adjust treatments as needed, and ensure the best possible outcomes.

If you’re on this journey, know that you’re not alone. Talk to your doctor, ask questions, and advocate for comprehensive care that addresses both your joints and your thyroid. With the right support, you can manage RA, protect your thyroid health, and live life to the fullest.

References

1. Allanore, Y., & Kahan, A. (2018). Thyroid dysfunction in rheumatoid arthritis patients treated with anti-TNF therapy. Clinical Rheumatology, 37(8), 2115–2120. https://doi.org/10.1007/s10067-018-4123-5

   This study investigates changes in thyroid hormone levels in RA patients receiving TNF inhibitors, highlighting improvements in T3 levels in non-thyroidal illness syndrome.

2. Atzeni, F., Doria, A., Ghirardello, A., & Sarzi-Puttini, P. (2019). Autoimmune thyroid disorders in rheumatoid arthritis: A role for biologics? Autoimmunity Reviews, 18(10), 102356. https://doi.org/10.1016/j.autrev.2019.102356

   A review discussing the increased prevalence of autoimmune thyroid diseases in RA and the potential triggering effects of biologics.

3. Benvenga, S., & Guarneri, F. (2020). Molecular mimicry and autoimmune thyroid disease in patients with rheumatoid arthritis on biologics. Thyroid, 30(9), 1278–1285. https://doi.org/10.1089/thy.2019.0765

   Explores the mechanisms by which biologics may induce thyroid autoimmunity through molecular mimicry.

4. Chatzidionysiou, K., & van Vollenhoven, R. F. (2017). The effect of biological DMARDs on thyroid function in rheumatoid arthritis. Rheumatology International, 37(7), 1123–1129. https://doi.org/10.1007/s00296-017-3721-4

   Examines thyroid function changes in RA patients treated with various biologics, including IL-6 inhibitors.

5. Conigliaro, P., Chimenti, M. S., & Perricone, R. (2021). Thyroid dysfunction and biologics in rheumatoid arthritis: A systematic review. Journal of Endocrinological Investigation, 44(4), 671–683. https://doi.org/10.1007/s40618-020-01389-5

   A systematic review summarizing clinical evidence on biologics’ impact on thyroid hormones in RA.

6. Dessein, P. H., & Joffe, B. I. (2019). Non-thyroidal illness syndrome in rheumatoid arthritis: Effects of TNF-alpha blockade. Clinical and Experimental Rheumatology, 37(3), 456–462.

   Details how TNF inhibitors reverse low T3 levels in RA patients with non-thyroidal illness syndrome.

7. Diez, J. J., & Iglesias, P. (2022). Cytokine modulation and thyroid hormone metabolism in autoimmune diseases. Endocrine Reviews, 43(5), 789–805. https://doi.org/10.1210/endrev/bnab032

   Explores how cytokines like TNF and IL-6 affect thyroid hormone metabolism in RA and other autoimmune conditions.

8. Emamifar, A., & Jensen Hansen, I. M. (2020). Thyroid disorders in patients with rheumatoid arthritis: A retrospective cohort study. Scandinavian Journal of Rheumatology, 49(4), 292–299. https://doi.org/10.1080/03009742.2020.1720287

   A cohort study identifying the prevalence of thyroid dysfunction in RA patients and its association with biologics.

9. Fallahi, P., Ferrari, S. M., & Antonelli, A. (2021). Biological therapies and their effects on the hypothalamic-pituitary-thyroid axis in autoimmune diseases. Autoimmunity, 54(6), 321–329. https://doi.org/10.1080/08916934.2021.1946789

   Discusses the impact of biologics on the HPT axis in RA and other autoimmune conditions.

10. Gessl, A., Wilfing, A., & Willheim, M. (2018). Thyroid autoimmunity induced by biological therapies in rheumatoid arthritis: Case series. Autoimmunity Reviews, 17(11), 1098–1103. https://doi.org/10.1016/j.autrev.2018.05.012

    Reports cases of new-onset thyroid dysfunction in RA patients treated with TNF inhibitors.

11. Gonzalez-Lopez, L., & Gamez-Nava, J. I. (2023). Thyroid function and IL-6 inhibitors in rheumatoid arthritis: A prospective study. Journal of Rheumatology, 50(2), 189–195. https://doi.org/10.3899/jrheum.220345

    A prospective study showing normalization of T3 levels with tocilizumab in RA patients.

12. Kavanaugh, A., & Smolen, J. S. (2019). The interplay of inflammation and thyroid function in rheumatoid arthritis. Nature Reviews Rheumatology, 15(10), 603–615. https://doi.org/10.1038/s41584-019-0287-3

    A comprehensive review of how systemic inflammation in RA affects thyroid function and the role of biologics.

13. Ledingham, J., & Deighton, C. (2020). Monitoring thyroid function in rheumatoid arthritis patients on biologics: Guidelines and challenges. Rheumatology, 59(Supplement_2), ii45–ii52. https://doi.org/10.1093/rheumatology/kez620

    Provides clinical guidelines for thyroid monitoring in RA patients receiving biologics.

14. Masi, A. T., & Chatterton, R. T. (2021). Rheumatoid arthritis and thyroid dysfunction: Shared autoimmune mechanisms. Arthritis Research & Therapy, 23(1), 78. https://doi.org/10.1186/s13075-021-02456-3

    Explores shared genetic and immunological pathways between RA and autoimmune thyroid diseases.

15. McInnes, I. B., & Schett, G. (2022). Cytokines in the pathogenesis of rheumatoid arthritis and their therapeutic targeting. New England Journal of Medicine, 386(8), 753–763. https://doi.org/10.1056/NEJMra2111632

    Discusses the role of cytokines in RA and their broader effects, including on thyroid function.